The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus

The advent of elexacaftor/tezacaftor/ivacaftor (ETI) resulted in unprecedented clinical benefits for eligible adults with CF. As a result, the question of whether chronic treatments can be safely stopped or adapted to this new situation has become a matter of great interest. Our objective was to derive a consensus among Italian experts on the impact of ETI on the current clinical management of CF lung disease.

Source: Respiratory Medicine - November 3, 2023 Category: Respiratory Medicine Authors: Andrea Gramegna, Stefano Aliberti, Maria Adelaide Calderazzo, Rosaria Casciaro, Clara Ceruti, Giuseppe Cimino, Benedetta Fabrizzi, Cristina Lucanto, Barbara Messore, Giovanna Pisi, Giovanni Taccetti, Paolo Tarsia, Francesco Blasi, Marco Cipolli Tags: Original Research Source Type: research